TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16411387
Drug: Otamixaban (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (escalating intravenous doses, 6-hour infusions: 1.7 to 183 microg/kg/h)
Study: 16411387
Drug: Otamixaban (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (bolus dose: 30 or 120 microg/kg with 6-hour infusion: 60 or 140 microg/kg/h)
Study: 8839525
Drug: Inhaled beta-agonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta-agonists
Study: 6432291
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus triple treatment (sodium fluoride, calcium, and vitamin D)
Study: 6432291
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Prednisone plus triple treatment and Only prednisone)
Study: 22369557
Drug: Long-term low
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term low dose aspirin therapy (75 mg and 150 mg)
Study: 22369557
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not taking aspirin)
Study: 11966498
Drug: Ranitidine, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 75 mg
Study: 7789484
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg q.d. oral therapy for 3 days
Study: 7789484
Drug: Clarithromycin, 250
Normalized name: Clarithromycin, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 250 mg b.i.d. oral therapy for 10 +/- 2 days
Study: 2887328
Drug: Cetirizine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 20 mg
Study: 29877199
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation combined with standard of care (SOC)
Study: 26477842
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) 1.25 mg
Study: 26477842
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) 0.5 mg
Study: 20224475
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (0.625 mg)
Study: 18160813
Drug: Mouthrinse with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinse with 0.2% NaF solution
Study: 18160813
Drug: Gels (0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gels (0.2% or 0.32%) alone and in combination with brushing
Study: 18160813
Drug: Interdental brush
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdental brush with fluoride gel after toothbrushing
Study: 15786539
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily)
Study: 15786539
Drug: Sofalcone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofalcone (100 mg thrice daily) plus the triple therapy
Study: 15786539
Drug: Polaprezinc (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (150 mg twice daily) plus the triple therapy
Study: 11389501
Drug: New antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antifungal agents (specific agents not mentioned)
Study: 9159561
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin once daily for 5 days
Study: 3655310
Drug: 12-week intramuscular
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intramuscular lymphoblastoid interferon treatment
Study: 3655310
Drug: 24-week intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week intramuscular lymphoblastoid interferon treatment
Study: 31304593
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg rectal misoprostol at urinary catheter insertion plus 400 μg rectally after abdominal closure (preoperative group, n=100)
Study: 31304593
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg of rectal misoprostol after abdominal closure (postoperative group, n=100)
Study: 28914260
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (Hd‐MTX) therapy (3 g/m2)
Study: 28914260
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (Id‐MTX) therapy (0.5 g/m2)
Study: 24642289
Drug: L-Dopa (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (150 mg)
Study: 20621900
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg/d subcutaneously for 28 +/- 4 days after receiving open-label enoxaparin for an initial 10 +/- 4 days.
Study: 16351767
Drug: Soyabean oil-based
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soyabean oil-based intravenous lipid emulsion (ILE)
Study: 11942872
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (Group E)
Study: 11942872
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (Group P)
Study: 2698567
Drug: Gallopamil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (3 X 50 mg daily for 4 weeks)
Study: 1093651
Drug: Co-trimoxazole (trimethoprim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - single dose
Study: 1093651
Drug: Co-trimoxazole (trimethoprim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - two doses
Study: 1093651
Drug: TMP-SDZ (sulfadiazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - single dose
Study: 1093651
Drug: TMP-SDZ (sulfadiazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - two doses
Study: 25272194
Drug: Maximum ARB
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum ARB dose
Study: 25272194
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg combination
Study: 19471949
Drug: IV siplizumab
Normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV siplizumab (0.012 mg/kg and 0.04 mg/kg) given every 2 weeks for 8 doses
Study: 19471949
Drug: SC siplizumab
Normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC siplizumab (5 mg for 12 weeks, 5 mg for 6 weeks, and 7 mg for 4 weeks)
Study: 16505664
Drug: Sequential gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential gas delivery (SGD) mask at 8 L/min
Study: 12867391
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily
Study: 12867391
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) at 10:00 PM
Study: 12867391
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC)
Study: 10550446
Drug: hPTH (1-34)
Normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH (1-34) 50 units weekly (L group)
Study: 10550446
Drug: hPTH (1-34)
Normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH (1-34) 100 units weekly (M group)
Study: 10550446
Drug: hPTH (1-34)
Normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH (1-34) 200 units weekly (H group)
Study: 10550446
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (L, M, H)
Study: 6375465
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg buprenorphine
Study: 6375465
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg buprenorphine
Study: 28558061
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose antimony
Study: 28558061
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antimony
Study: 26775868
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of SNEDDS with conventional cinnarizine tablet
Study: 21929736
Drug: Telmisartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40-80 mg daily)
Study: 17468653
Drug: Xylitol (9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (9.6 g daily, 3 times a day)
Study: 17468653
Drug: Control product
Normalized name: Patch test control product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control product (0.5 g daily, 3 times a day)
Study: 9778325
Drug: 30000 IU
Normalized name: protease 30000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30000 IU heparin with 10.5 g SNAC
Study: 9778325
Drug: 30000 IU
Normalized name: protease 30000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30000 IU heparin alone
Study: 9778325
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g SNAC alone
Study: 9778325
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g SNAC with heparin 30000 to 150000 IU
Study: 8154249
Drug: Topical carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical carteolol 2%
Study: 27893955
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) high dose
Study: 27893955
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) medium dose
Study: 18990531
Drug: Intravenous tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tigecycline
Study: 9233110
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution IV
Study: 7967102
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (quantity in g/week and frequency in times/week)
Study: 2502065
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg
Study: 2502065
Drug: Fleroxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (200 or 400 mg)
Study: 28328159
Drug: fosdagrocorat 10
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosdagrocorat 10 mg
Study: 28328159
Drug: fosdagrocorat 25
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosdagrocorat 25 mg
Study: 28328159
Drug: prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone 5 mg
Study: 19755817
Drug: S-1/Irinotecan (CPT-11)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1/Irinotecan (CPT-11) therapy
Study: 16752738
Drug: Drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and physiotherapeutic factors
Study: 7954035
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg starting dose, increased to 8 mg if DBP > 95 mmHg)
Study: 7954035
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg dose)
Study: 2262897
Drug: Atropine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 2.0 mg
Study: 2262897
Drug: Atropine 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 4.0 mg
Study: 3579820
Drug: Atropine (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5, 1.0, 2.0, 4.0 mg)
Study: 3579820
Drug: Atropine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 2.0 mg and 4.0 mg
Study: 30145102
Drug: 14-day bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth-containing quadruple therapy (group A)
Study: 30145102
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy supplemented with Clostridium butyricum (group B)
Study: 20093548
Drug: Apligraf (Organogenesis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apligraf (Organogenesis, Inc) used in conjunction with standard therapy (sharp debridement, standard wound care, and off-loading)
Study: 8532099
Drug: Psychoeducational training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational training for medication management, cognitive therapy, and work with relatives' groups
Study: 8532099
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including neuroleptic relapse prevention
Study: 30939851
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (60 mg kg‐1 24 h‐¹)
Study: 29771088
Drug: Omeprazole enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 1 month
Study: 29771088
Drug: Omeprazole enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 2 months
Study: 29771088
Drug: Omeprazole enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 3 months
Study: 29771088
Drug: Omeprazole enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 4 months
Study: 26917577
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (2 g/day for 1 month)
Study: 22138866
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (HCHO; 7 g/kg body weight)
Study: 22138866
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (LCHO; 2 g/kg body weight)
Study: 15743362
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h
Study: 15743362
Drug: Terlipressin 2
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 2 mg intravenous bolus
Study: 9469362
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 microg/kg/day administered subcutaneously on days 3 through 9 after each BOP and on days 6 through 19 after each VIP, BEP, or EP cycle
Study: 7630200
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone for patients < 40 years old
Study: 2118326
Drug: Cefazolin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1-g doses, three postoperative)
Study: 2118326
Drug: Ceftriaxone (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1-g single dose preoperative)
Study: 318965
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of terbutaline sulfate
Study: 318965
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of epinephrine hydrochloride
Study: 23870605
Drug: Test formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation: Amlodipine orotate 10 mg and valsartan 160 mg
Study: 23870605
Drug: Reference formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation: Amlodipine besylate 10 mg and valsartan 160 mg
Study: 20980201
Drug: Telmisartan (Angiotensin-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (Angiotensin-receptor blocker)
Study: 20980201
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ramipril + telmisartan)
Study: 17464690
Drug: Haloperidol or
Normalized name: haloperidol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol or risperidone for 8 weeks (exact dosage not specified)
Study: 10211026
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg kg‐1 (group TH)
Study: 10211026
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 micrograms kg‐1 and propofol 3 mg kg‐1 (group PAH)
Study: 2180661
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy aimed at near normalization of blood glucose levels
Study: 1776591
Drug: Chlormethiazole (384
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole (384 mg)
Study: 30677465
Drug: Treat-and-extend (T&E)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treat-and-extend (T&E) regimen with intravitreal ranibizumab at a dose of 0.5 mg
Study: 30677465
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing regimen with intravitreal ranibizumab at a dose of 0.5 mg
Study: 30677465
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing regimen
Study: 28605779
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin and clopidogrel) for 24 months
Study: 28605779
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin and clopidogrel) for 6 months
Study: 19723755
Drug: Iodine-131 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-131 treatment
Study: 19723755
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (antithyroid drugs)
Study: 11561769
Drug: FEC (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (5-fluorouracil, epirubicin, and cyclophosphamide) - 9 cycles with dose escalation
Study: 11561769
Drug: CTCb (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTCb (3 cycles of FEC followed by high-dose chemotherapy with alkylating agents)
Study: 30630803
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Dexmedetomidine + Continuous Positive Airway Pressure)
Study: 26614548
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy only
Study: 25885506
Drug: Intravenous 1
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1 g tranexamic acid 20 min before skin incision
Study: 2032107
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral lactulose (n = 35)
Study: 2032107
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium deoxycholate (n = 32)
Study: 2032107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment, n = 35)
Study: 6754509
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 mg t.d.s.
Study: 6754509
Drug: propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 160 mg b.d.
Study: 26885881
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA (women)
Study: 26885881
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg DHEA (men)
Study: 26885881
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg T (men)
Study: 21331473
Drug: HPMC capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC capsules
Study: 8057000
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 or 100 mg/day)
Study: 8057000
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 or 150 mg/day)
Study: 3127265
Drug: Ranitidine (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (H2 blocker)
Study: 31051499
Drug: Pistachio-supplemented diet
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio-supplemented diet (PD, 50 E% carbohydrates and 33 E% fat, including 57 g pistachios/d)
Study: 27488933
Drug: Ramosetron 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.45 mg
Study: 27488933
Drug: Ramosetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (all doses)
Study: 14562597
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha gel
Study: 7599911
Drug: Metosil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metosil (10 mg)
Study: 7599911
Drug: Plasil BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasil BP (10 mg)
Study: 2221413
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g carnitine intravenously before cardiopulmonary bypass (CPB)
Study: 2221413
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g carnitine intravenously before cardiopulmonary bypass (CPB)
Study: 30798143
Drug: Parent administered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent administered resilience component in conjunction with stuttering therapy